Our data provide important preclinical evidence of the efficacy and safety of the VLP-based Cas9/gRNA RNP therapeutic approach, implying that gene editing of brachyury may provide a novel therapeutic paradigm for chordoma patients that warrants further investigation. Here, TBX1 is linked to chordoma.